Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
The FIND Study
NCT07315373Phase 1Not yet recruiting
- Sponsor
- Peking University People's Hospital
- Start
- Dec 2025
- Primary completion
- Dec 2028
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
01
Overview
Phase 1, open-label trial of zanubrutinib in immune thrombocytopenia (ITP) (3 arms), sponsored by Peking University People's Hospital. Primary endpoint: Sustained response at 26 weeks. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
zanubrutinib
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT07315373.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07315373.